Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Conclusions:
Glycemic control with empagliflozin significantly ameliorated cardiovascular injury and remodeling, vascular dysfunction, and cognitive decline in obese and type 2 diabetic mice. Thus, empagliflozin seems to be potentially a promising therapeutic agent for diabetic macrovascular disease and cognitive decline.
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Bowen LinNobutaka KoibuchiYu HasegawaDaisuke SuetaKensuke ToyamaKen UekawaMingJie MaTakashi NakagawaHiroaki KusakaShokei Kim-Mitsuyama Source Type: research
More News: Brain | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Empagliflozin | Endocrinology | Heart | Jardiance | Neurology | Obesity | SGLT2 Inhibitors